The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
NCT01610934 on ClinicalTrials.gov · last registry update 2013-09-05
A small phase 2/phase 3 — 15 participants, against a typical 60. The sponsor logged completion for August 2013. Primary outcome, as filed: Fasting Plasma Glucose.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University Hospital, Gentofte, Copenhagen
- Sponsor type
- Other
- Enrollment
- 15
- Started
- 2012-08
- Primary completion
- 2013-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Fasting Plasma Glucose
Conditions studied
Maturity-onset Diabetes of the Young
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.